CN111848423A - Preparation method of tert-butyl 3-oxocyclobutylcarbamate - Google Patents

Preparation method of tert-butyl 3-oxocyclobutylcarbamate Download PDF

Info

Publication number
CN111848423A
CN111848423A CN201910360376.6A CN201910360376A CN111848423A CN 111848423 A CN111848423 A CN 111848423A CN 201910360376 A CN201910360376 A CN 201910360376A CN 111848423 A CN111848423 A CN 111848423A
Authority
CN
China
Prior art keywords
compound
acid
unsubstituted
tert
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201910360376.6A
Other languages
Chinese (zh)
Other versions
CN111848423B (en
Inventor
竺伟
袁利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SYNCOZYMES (SHANGHAI) CO Ltd
Original Assignee
SYNCOZYMES (SHANGHAI) CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SYNCOZYMES (SHANGHAI) CO Ltd filed Critical SYNCOZYMES (SHANGHAI) CO Ltd
Priority to CN201910360376.6A priority Critical patent/CN111848423B/en
Publication of CN111848423A publication Critical patent/CN111848423A/en
Application granted granted Critical
Publication of CN111848423B publication Critical patent/CN111848423B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C221/00Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/12Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention belongs to the technical field of medicines, and particularly relates to a preparation method of tert-butyl 3-oxocyclobutyl carbamate (I), which comprises the following steps: and protecting the compound IV to generate a compound III, performing Hofmann degradation reaction to obtain a compound II, and finally performing deprotection to obtain a compound I. Compared with the prior art, the method has the advantages of low cost of the technical route, mild reaction conditions, no use of toxic reagents with large risk coefficients, environmental protection and good application value.

Description

Preparation method of tert-butyl 3-oxocyclobutylcarbamate
The technical field is as follows:
the invention belongs to the technical field of medicines, and particularly relates to a preparation method of tert-butyl 3-oxocyclobutylcarbamate.
Background art:
aminocyclobutane, as an important molecular scaffold, is widely used in the design of new drug molecules, such as drugs for treating hepatitis c virus infection (WO 2013064538); LSD1 inhibitors containing an aminocyclobutane skeleton (WO 2013057322); aminocyclobutane-containing JAK and SYK inhibitors (WO 2013030138); 1, 3-cyclobutanediamine containing aminocyclobutane (CN 104829492); aminocyclobutane containing elvan intermediate (WO2015010297, WO2013107291 and WO 2013107405). And tert-butyl 3-oxocyclobutylcarbamate (CAS number: 154748-49-9) having an aminocyclobutane structure is an important intermediate for synthesizing such compounds. There are several publications reporting the synthesis of tert-butyl 3-oxocyclobutylcarbamate.
Patents WO2015010297, WO2013107291 and WO2013107405 all disclose processes for the preparation of tert-butyl 3-oxocyclobutylcarbamate starting from 3-oxocyclobutanecarboxylic acid, the route being as in Scheme 1.
Figure BDA0002046673060000011
The 3-oxocyclobutanecarboxylic acid is used as a raw material, and tert-butyl 3-oxocyclobutyl carbamate is obtained through three reactions of chlorination, substitution and rearrangement. Column chromatography purification is used for a plurality of times in the reaction process, and NaN is used3And the like, and is not suitable for industrial production.
Patent WO2017019589 discloses a process for preparing tert-butyl 3-oxocyclobutylcarbamate from 3-oxocyclobutanecarboxylic acid as a starting material, the route being shown in Scheme 2.
Figure BDA0002046673060000021
The 3-oxocyclobutanecarboxylic acid is used as a raw material in the route, although the 3-oxocyclobutanecarboxylic acid tert-butyl carbamate is obtained through one-step reaction, the yield is only 47%, and the requirement of industrial production cannot be met.
Patents WO2011044503, WO2010147836, WO2010132777 and the like disclose methods for preparing tert-butyl 3-oxocyclobutylcarbamate from 3-methylenecyclobutylcarbonitrile as a raw material, and routes are shown in Scheme 3.
Figure BDA0002046673060000022
The 3-oxocyclobutylcarbamic acid tert-butyl ester is obtained by using 3-methylenecyclobutylnitrile as a raw material through three-step reaction in the route, the yield is extremely low and is only 25%, and NaN is used 3And the like, and is not suitable for industrial production.
The invention content is as follows:
in order to overcome the defects in the prior art, the invention discloses a preparation method of tert-butyl 3-oxocyclobutylcarbamate.
The specific process route is as follows:
Figure BDA0002046673060000023
wherein R is halogen substituted or unsubstituted C1-C6 alkyl, unsubstituted C3-C6 cycloalkyl, unsubstituted benzyl, or benzyl substituted with halogen.
In order to achieve the purpose, the invention adopts the following technical scheme:
step a): the compound IV is protected to generate a compound III,
step b): carrying out Hoffman degradation reaction on the compound III to obtain a compound II,
step c): deprotection of compound II produces compound I.
Further, R in the scheme is methyl or ethyl, preferably ethyl.
Further, the compound IV in step a) is reacted with trimethyl orthoformate or triethyl orthoformate to give compound III, preferably triethyl orthoformate.
Further, the reaction of step a) is carried out under the action of a catalyst selected from sulfuric acid, p-toluenesulfonic acid, benzenesulfonic acid, acetic acid, preferably p-toluenesulfonic acid.
Further, an oxidant is used in the Hofmann degradation reaction in the step b), and the oxidant is selected from NaClO, NaBrO and Br 2NaOH, preferably NaClO.
Further, the hofmann degradation reaction of step b) is carried out in an organic solvent selected from tetrahydrofuran, dichloromethane, 1, 4-dioxane, preferably tetrahydrofuran.
Further, the deprotection reaction in the step c) is carried out under the condition of an acid catalyst, and the acid catalyst is selected from hydrochloric acid and sulfuric acid.
Further, the acid concentration in the deprotection reaction of step c) is selected from 0.1 to 1mol/L, preferably 0.5 to 1 mol/L.
Compared with the prior art, the method has the advantages of low cost of the used technical route, mild reaction conditions, no use of toxic reagents with large risk coefficients, environmental friendliness, high yield and suitability for industrial production.
Drawings
Process for preparation of compound III of FIG. 11HNMR picture
FIG. 2 Process for preparation of Compound II1HNMR picture
FIG. 3 Process for preparation of Compound I1HNMR picture
Detailed Description
The technical content of the present invention is further described below with reference to specific examples for better understanding of the content of the present invention, but the scope of the present invention is not limited thereto.
EXAMPLE 1 preparation of Compound III
Adding 50g of compound IV into 200mL of ethanol, then adding 3.8g of p-toluenesulfonic acid, cooling to 0-5 ℃, dropwise adding 79g of triethyl orthoformate, reacting at room temperature for 20h after completing dropwise adding, and tracking by TLC until the reaction is completed. Extracting with dichloromethane, concentrating to dryness, adding 50mL methyl tert-butyl ether, pulping, filtering, washing, and oven drying to obtain white solid 75g, with yield 91% and purity 98%. 1The H NMR data are shown in FIG. 1.
EXAMPLE 2 preparation of Compound III
Adding 50g of compound IV into 200mL of ethanol, then adding 2.2g of concentrated sulfuric acid, cooling to 0-5 ℃, dropwise adding 79g of triethyl orthoformate, reacting at room temperature for 20h after the dropwise adding is finished, and tracking by TLC until the reaction is finished. Extracting with dichloromethane, concentrating to dryness, adding 50mL methyl tert-butyl ether, pulping, filtering, washing, and oven drying to obtain white solid 71g, with yield of 86% and purity of 98%.
EXAMPLE 3 preparation of Compound III
Adding 50g of compound IV into 200mL of methanol, then adding 3.8g of p-toluenesulfonic acid, cooling to 0-5 ℃, slowly dripping 57g of trimethyl orthoformate, reacting at room temperature for 20h after dripping, and tracking by TLC until the reaction is finished. Extracting with dichloromethane, concentrating to dryness, adding 50mL methyl tert-butyl ether, pulping, filtering, washing, and oven drying to obtain 62g white solid with yield of 88% and purity of 98%.
EXAMPLE 4 preparation of Compound III
Adding 50g of compound IV into 200mL of ethanol, then adding 2.2g of concentrated sulfuric acid, cooling to 0-5 ℃, dropwise adding 100g of tripropylorthoformate, reacting at room temperature for 20h after the dropwise addition is finished, and tracking by TLC until the reaction is finished. Extracting with dichloromethane, concentrating to dryness, adding 50mL methyl tert-butyl ether, pulping, filtering, washing, and drying to obtain 57g white solid.
EXAMPLE 5 preparation of Compound III
Adding 50g of compound IV into 200mL of ethanol, then adding 2.2g of concentrated sulfuric acid, cooling to 0-5 ℃, dropwise adding 123g of tributyl orthoformate, reacting at room temperature for 20h after the dropwise adding is finished, and tracking by TLC until the reaction is finished. Extracting with dichloromethane, concentrating to dryness, adding 50mL methyl tert-butyl ether, pulping, filtering, washing, and drying to obtain 62g of white solid.
EXAMPLE 6 preparation of Compound II
50g of the compound III obtained in example 1 was added to 200mL of tetrahydrofuran, cooled to 0 ℃, and then 21g of sodium hydroxide was dissolved in 240g of a sodium hypochlorite (10%) solution and added dropwise to the reaction system. And (3) carrying out reaction at 0-5 ℃, tracking by TLC until the reaction is finished, then adding 58g of di-tert-butyl dicarbonate, tracking by TLC until the reaction is finished, extracting by using dichloromethane, concentrating to dryness to obtain 66g of a crude product of the compound II, and directly using the crude product in the next step.1The H NMR data are shown in FIG. 2.
EXAMPLE 7 preparation of Compound II
50g of the compound III obtained in example 3 was added to 200mL of tetrahydrofuran, cooled to 0 ℃ and then 21g of sodium hydroxide was dissolved in 384g of a sodium hypobromite (10%) solution and added dropwise to the reaction system. And (3) reacting at 0-5 ℃, tracking by TLC until the reaction is finished, adding 58g of di-tert-butyl dicarbonate, tracking by TLC until the reaction is finished, extracting by using dichloromethane, and concentrating to dryness to obtain 63g of a crude product of the compound II, wherein the crude product is directly used in the next step.
EXAMPLE 8 preparation of Compound I
66g of the compound II prepared in example 6 were added to 120mL of tetrahydrofuran, and then 120mL of 0.5mol/L dilute sulfuric acid was added, stirred at room temperature for 20 hours, concentrated to remove tetrahydrofuran, cooled, filtered, washed, and dried to obtain 43g of a white solid, yield 87% (total of two steps), and purity 99%.1The H NMR data are shown in FIG. 3.
EXAMPLE 9 preparation of Compound I
63g of the compound II prepared in example 7 was added to 120mL of tetrahydrofuran, 120mL of 1mol/L diluted hydrochloric acid was added, the mixture was stirred at room temperature for 20 hours, the tetrahydrofuran was removed by concentration, and the mixture was cooled, filtered, washed and dried to obtain 47g of a white solid, yield 81% (total of the two steps) and purity 99%.

Claims (8)

1. A process for the preparation of the compound tert-butyl 3-oxocyclobutylcarbamate (compound I), comprising the steps of:
step a): the compound IV is protected to generate a compound III,
step b): carrying out Hoffman degradation reaction on the compound III to obtain a compound II,
step c): deprotecting compound II to produce compound I;
the specific route is as follows:
Figure FDA0002046673050000011
wherein R is halogen substituted or unsubstituted C1-C6 alkyl, unsubstituted C3-C6 cycloalkyl, unsubstituted benzyl, or benzyl substituted with halogen.
2. The method of claim 1, wherein: reacting the compound IV in the step a) with trimethyl orthoformate or triethyl orthoformate to obtain a compound III.
3. The method of claim 1, wherein: step a) is carried out under the action of a catalyst selected from sulfuric acid, p-toluenesulfonic acid, benzenesulfonic acid and acetic acid.
4. The method of claim 1, wherein: using an oxidant in the Hofmann degradation reaction in the step b), wherein the oxidant is selected from NaClO, NaBrO and Br2/NaOH。
5. The method of claim 1, wherein: the Hofmann degradation reaction in the step b) is carried out in an organic solvent, wherein the organic solvent is selected from tetrahydrofuran, dichloromethane and 1, 4-dioxane.
6. The method of claim 1, wherein: and c) carrying out deprotection reaction under the condition of an acid catalyst, wherein the acid catalyst is selected from hydrochloric acid and sulfuric acid.
7. The method of claim 1, wherein: the concentration of the acid in the deprotection reaction in the step c) is selected from 0.1-1 mol/L.
8. A compound shown as a formula III is used for preparing 3-oxocyclobutylcarbamic acid tert-butyl ester.
Figure FDA0002046673050000021
Wherein R is halogen substituted or unsubstituted C1-C6 alkyl, unsubstituted C3-C6 cycloalkyl, unsubstituted benzyl, or benzyl substituted with halogen.
CN201910360376.6A 2019-04-30 2019-04-30 Preparation method of tert-butyl 3-oxocyclobutylcarbamate Active CN111848423B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910360376.6A CN111848423B (en) 2019-04-30 2019-04-30 Preparation method of tert-butyl 3-oxocyclobutylcarbamate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910360376.6A CN111848423B (en) 2019-04-30 2019-04-30 Preparation method of tert-butyl 3-oxocyclobutylcarbamate

Publications (2)

Publication Number Publication Date
CN111848423A true CN111848423A (en) 2020-10-30
CN111848423B CN111848423B (en) 2022-10-14

Family

ID=72966507

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910360376.6A Active CN111848423B (en) 2019-04-30 2019-04-30 Preparation method of tert-butyl 3-oxocyclobutylcarbamate

Country Status (1)

Country Link
CN (1) CN111848423B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024140678A1 (en) * 2022-12-27 2024-07-04 Beigene (Suzhou) Co., Ltd. A ketal protected intermediate for sonrotoclax and preparation method thereof

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064961A (en) * 1989-12-18 1991-11-12 E. R. Squibb & Sons, Inc. Process for preparing an optically active cyclobutane nucleoside
EP1170281A1 (en) * 2000-06-27 2002-01-09 Les Laboratoires Servier 1,1- and 1,2-disubstituted cyclopropanes, process for their preparation and pharmaceutical compositions thereof
WO2004056725A1 (en) * 2002-12-20 2004-07-08 Ge Healthcare Limited Solid-phase preparation of 18f-labelled amino acids
CN101070322A (en) * 2007-03-26 2007-11-14 中国医学科学院医药生物技术研究所 7-(4-nitroyl-3-amino-1-piperidyl) quinolinecarboxylic acid derivative, its preparing method and use
US20080280879A1 (en) * 2007-05-09 2008-11-13 Pfizer Inc Substituted heterocyclic derivatives and their pharmaceutical use and compositions
CN104244932A (en) * 2011-10-19 2014-12-24 马尔斯公司 Inhibitors of arginase and their therapeutic applications
CN105130879A (en) * 2015-07-24 2015-12-09 沧州那瑞化学科技有限公司 Preparation method of (R)-3-Boc-aminopiperidine
WO2016008582A1 (en) * 2014-07-15 2016-01-21 Grünenthal GmbH Substituted azaspiro(4.5)decane derivatives
CN105315161A (en) * 2015-06-05 2016-02-10 厦门医学高等专科学校 Method for preparing key intermediate of PKB/Akt inhibitor
WO2017019487A1 (en) * 2015-07-24 2017-02-02 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
WO2017065473A1 (en) * 2015-10-12 2017-04-20 Chong Kun Dang Pharmaceutical Corp. Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
CN107253940A (en) * 2017-07-21 2017-10-17 苏州信恩医药科技有限公司 Application of the asymmetric o conjugate addition reactions in the synthesis of Ao Gelieting intermediates
CN109053496A (en) * 2018-08-09 2018-12-21 吉尔生化(上海)有限公司 A kind of synthetic method of 3-Boc- aminomethyl cyclobutanone
CN112236415A (en) * 2017-12-26 2021-01-15 赛特凯恩蒂克公司 Process for preparing aminopyrimidines and intermediates thereof

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064961A (en) * 1989-12-18 1991-11-12 E. R. Squibb & Sons, Inc. Process for preparing an optically active cyclobutane nucleoside
EP1170281A1 (en) * 2000-06-27 2002-01-09 Les Laboratoires Servier 1,1- and 1,2-disubstituted cyclopropanes, process for their preparation and pharmaceutical compositions thereof
WO2004056725A1 (en) * 2002-12-20 2004-07-08 Ge Healthcare Limited Solid-phase preparation of 18f-labelled amino acids
CN101070322A (en) * 2007-03-26 2007-11-14 中国医学科学院医药生物技术研究所 7-(4-nitroyl-3-amino-1-piperidyl) quinolinecarboxylic acid derivative, its preparing method and use
US20080280879A1 (en) * 2007-05-09 2008-11-13 Pfizer Inc Substituted heterocyclic derivatives and their pharmaceutical use and compositions
CN104244932A (en) * 2011-10-19 2014-12-24 马尔斯公司 Inhibitors of arginase and their therapeutic applications
WO2016008582A1 (en) * 2014-07-15 2016-01-21 Grünenthal GmbH Substituted azaspiro(4.5)decane derivatives
CN105315161A (en) * 2015-06-05 2016-02-10 厦门医学高等专科学校 Method for preparing key intermediate of PKB/Akt inhibitor
CN105130879A (en) * 2015-07-24 2015-12-09 沧州那瑞化学科技有限公司 Preparation method of (R)-3-Boc-aminopiperidine
WO2017019487A1 (en) * 2015-07-24 2017-02-02 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
WO2017065473A1 (en) * 2015-10-12 2017-04-20 Chong Kun Dang Pharmaceutical Corp. Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
CN107253940A (en) * 2017-07-21 2017-10-17 苏州信恩医药科技有限公司 Application of the asymmetric o conjugate addition reactions in the synthesis of Ao Gelieting intermediates
CN112236415A (en) * 2017-12-26 2021-01-15 赛特凯恩蒂克公司 Process for preparing aminopyrimidines and intermediates thereof
CN109053496A (en) * 2018-08-09 2018-12-21 吉尔生化(上海)有限公司 A kind of synthetic method of 3-Boc- aminomethyl cyclobutanone

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FREDERICK F. CASERIO等: "Small-ring compounds.XXI. 3-Methylenecyclobutanone and related compounds", 《3-METHYLENECYCLOBUTANONE》 *
GREGORY S. BISACCHI等: "Synthesis and antiviral activity of anantiomeric forms of cyclobutyl nucleoside analogues", 《J. MED. CHEM.》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024140678A1 (en) * 2022-12-27 2024-07-04 Beigene (Suzhou) Co., Ltd. A ketal protected intermediate for sonrotoclax and preparation method thereof

Also Published As

Publication number Publication date
CN111848423B (en) 2022-10-14

Similar Documents

Publication Publication Date Title
KR101115412B1 (en) New preparation of hydroxychloroquine
CN109516998B (en) Synthesis method of Barosavir intermediate
JP2009502814A (en) Production of N-substituted isothiazolinone derivatives
CN113072436A (en) Preparation method of benzyl aryl ether
CN111848423B (en) Preparation method of tert-butyl 3-oxocyclobutylcarbamate
EA036663B1 (en) Method for preparing azoxystrobin
CN111302966A (en) Preparation method of mirabegron intermediate
CN107868033B (en) Preparation method of phenylalanine compound
CN111004141B (en) New method for synthesizing nintedanib intermediate 2-chloro-N-methyl-N- (4-nitrophenyl) acetamide
CN111018782B (en) Preparation method of 9-aminoacridine and derivatives thereof
JP2015526507A (en) Method for purifying fluvoxamine free base and method for producing high purity fluvoxamine maleate using the same
CN114560862A (en) Synthesis method of pyrrolo [1,2-A ] quinoxaline-4 (5H) -ketone and derivative thereof
CN113461538A (en) Preparation method of 2-chloro-3-bromoaniline
CN114195684B (en) Synthesis method of amino protecting group N-substituted chiral amino acid
KR100881890B1 (en) Method for preparing safogrelate hydrochloride
AU2020259813A1 (en) Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives
CN110724098A (en) Synthetic method of 5, 7-dichloro-1, 2,3, 4-tetrahydroisoquinoline-6-carboxylic acid hydrochloride
CN112341406B (en) Synthesis method of trans-4- [4- (3-methoxy-4-nitrophenyl) -1-piperazinyl ] adamantane-1-ol
CN113387874B (en) Method for synthesizing 6, 6-dialkyl piperidine-2-carboxylic acid compound
CN111217709A (en) Preparation method of (1-fluorocyclopropyl) methylamine hydrochloride
JP2003119197A (en) Method for producing 2-amino-6-cyclopropylamino-9h- purine
US4338259A (en) Alpha-halogeno-beta-aminopropionitriles or the mineral acid salts thereof, and processes for production thereof
CN119350202A (en) Preparation method of 4-cyanophenyl isothiocyanate
CN118994060A (en) Method for green synthesis of amide derivatives by using trichlorotoluene
CN113735693A (en) Synthesis method of resveratrol monomethyl ether

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant